New treatment options for lupus – a focus on belimumab

References

• BreedveldFCCombeBUnderstanding emerging treatment paradigms in rheumatoid arthritisArthritis Res Ther201113Suppl 1S321624182
   PubMedGoogle Scholar
• Human Genome Sciences, IncArthritis Advisory Committee Meeting Briefing Document for the November 16, 2010 Meeting: Belimumab BENLYSTA® (Belimumab) Treatment of Systemic Lupus Erythematosus BLA 125370 [cited October 13, 2010]. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ArthritisDrugsAdvisoryCommittee/UCM233581.pdfAccessed January 5, 2012
   Google Scholar
• European Medicines Agency [homepage on the Internet]Benlystabelimumab [cited August 8, 2011]. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002015/human_med_001466.jsp&mid=WC0b01ac058001d124Accessed January 5, 2012
   Google Scholar
• SanzIYasothanUKirkpatrickPBelimumabNat Rev Drug Discov201110533533621532557
   PubMed Web of Science ®Google Scholar
• MerrillJTNeuweltCMWallaceDJEfficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trialArthritis Rheum201062122223320039413
   PubMed Web of Science ®Google Scholar
• Ramos-CasalsMDíaz-LagaresCKhamashtaMARituximab and lupus: good in real life, bad in controlled trialsArthritis Rheum20096191281128219714598
   PubMed Web of Science ®Google Scholar
• WeintraubBBelimumab efficacy is ‘mild’ but market potential still great: anticipating us approval of the first lupus drug since 1957BioDrugs201125320320521627345
   PubMed Web of Science ®Google Scholar
• MitkaMTreatment for lupus, first in 50 years, offers modest benefits, hope to patientsJAMA2011305171754175521540415
   PubMed Web of Science ®Google Scholar
• NavarraSVGuzmánRMGallacherAEEfficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trialLancet2011377976772173121296403
   PubMed Web of Science ®Google Scholar
• FurieRPetriMZamaniOA phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosusArthritis Rheum201163123918393022127708
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug AdministrationGuidance for Industry on Systemic Lupus Erythematosus – Developing Drugs for Treatment [cited Jun 2010]. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072063.pdfAccessed January 5, 2012
   Google Scholar
• TsokosGCSystemic lupus erythematosusN Engl J Med2011365222110212122129255
   PubMed Web of Science ®Google Scholar
• Pons-EstelGJAlarcónGSScofieldLReinlibLCooperGSUnderstanding the epidemiology and progression of systemic lupus erythematosusSemin Arthritis Rheum201039425726819136143
   PubMed Web of Science ®Google Scholar
• BertsiasGIoannidisJPBoletisJEULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including TherapeuticsAnn Rheum Dis200867219520517504841
   PubMed Web of Science ®Google Scholar
• KuznikABencinaMSvajgerUJerasMRozmanBJeralaRMechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolinesJ Immunol201118684794480421398612
   PubMed Web of Science ®Google Scholar
• Pons-EstelGJAlarcónGSGonzálezLAPossible protective effect of hydroxychloroquine on delaying the occurrence of integument damage in lupus: LXXI, data from a multiethnic cohortArthritis Care Res2010623393400
   Web of Science ®Google Scholar
• PaluckaAKBlanckJPBennettLPascualVBanchereauJCross- regulation of TNF and IFN-alpha in autoimmune diseasesProc Natl Acad Sci U S A200510293372337715728381
   PubMed Web of Science ®Google Scholar
• RönnblomLAlmGVElorantaMLThe type I interferon system in the development of lupusSemin Immunol201123211312121292501
   PubMed Web of Science ®Google Scholar
• MoorePABelvedereOOrrABLyS: member of the tumor necrosis factor family and B lymphocyte stimulatorScience1999285542526026310398604
   PubMed Web of Science ®Google Scholar
• OhataJZvaiflerNJNishioMFibroblast-like synoviocytes of mesenchymal origin express functional B cell-activating factor of the TNF family in response to proinflammatory cytokinesJ Immunol2005174286487015634908
   PubMed Web of Science ®Google Scholar
• ScapiniPCarlettoANardelliBProinflammatory mediators elicit secretion of the intracellular B-lymphocyte stimulator pool (BLyS) that is stored in activated neutrophils: implications for inflammatory diseasesBlood2005105283083715358625
   PubMed Web of Science ®Google Scholar
• KhareSDSarosiIXiaXZSevere B cell hyperplasia and autoimmune disease in TALL-1 transgenic miceProc Natl Acad Sci U S A20009773370337510716715
   PubMed Web of Science ®Google Scholar
• MackayFWoodcockSALawtonPMice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestationsJ Exp Med1999190111697171010587360
   PubMed Web of Science ®Google Scholar
• GrossJAJohnstonJMudriSTACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune diseaseNature2000404678199599910801128
   PubMed Web of Science ®Google Scholar
• ZhangJRoschkeVBakerKPCutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosusJ Immunol2001166161011123269
   PubMed Web of Science ®Google Scholar
• StohlWMetyasSTanSMB lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observationsArthritis Rheum200348123475348614673998
   PubMed Web of Science ®Google Scholar
• RoschkeVSosnovtsevaSWardCDBLyS and APRIL form biologically active heterotrimers that are expressed in patients with systemic immune-based rheumatic diseasesJ Immunol200216984314432112370363
   PubMed Web of Science ®Google Scholar
• CandonSGottenbergJEBengoufaDChatenoudLMarietteXQuantitative assessment of antibodies to ribonucleoproteins in primary Sjögren syndrome: correlation with B-cell biomarkers and disease activityAnn Rheum Dis20096871208121218713786
   PubMed Web of Science ®Google Scholar
• SchneeweisCRafalowiczMFeistEIncreased levels of BLyS and sVCAM-1 in anti-neutrophil cytoplasmatic antibody (ANCA)-associated vasculitides (AAV)Clin Exp Rheumatol2010281 Suppl 57626620412705
   PubMed Web of Science ®Google Scholar
• KarpusasMCacheroTGQianFCrystal structure of extracellular human BAFF, a TNF family member that stimulates B lymphocytesJ Mol Biol200231551145115411827482
   PubMed Web of Science ®Google Scholar
• BossenCCacheroTGTardivelATACI, unlike BAFF-R, is solely activated by oligomeric BAFF and APRIL to support survival of activated B cells and plasmablastsBlood200811131004101217942754
   PubMed Web of Science ®Google Scholar
• DillonSRHarderBLewisKBB-lymphocyte stimulator/a proliferation-inducing ligand heterotrimers are elevated in the sera of patients with autoimmune disease and are neutralized by atacicept and B-cell maturation antigen-immunoglobulinArthritis Res Ther2010122R4820302641
   PubMed Web of Science ®Google Scholar
• YaccobySPennisiALiXAtacicept (TACI-Ig) inhibits growth of TACI(high) primary myeloma cells in SCID-hu mice and in coculture with osteoclastsLeukemia200822240641318046446
   PubMed Web of Science ®Google Scholar
• KimJGrossJADillonSRIncreased BCMA expression in lupus marks activated B cells, and BCMA receptor engagement enhances the response to TLR9 stimulationAutoimmunity2011442698121250838
   PubMed Web of Science ®Google Scholar
• MorelJRoubilleCPlanellesLSerum levels of tumour necrosis factor family members a proliferation-inducing ligand (APRIL) and B lymphocyte stimulator (BLyS) are inversely correlated in systemic lupus erythematosusAnn Rheum Dis2009686997100218676986
   PubMed Web of Science ®Google Scholar
• HartungHPKieseierBCAtacicept: targeting B cells in multiple sclerosisTher Adv Neurol Disord20103420521621179612
   PubMedGoogle Scholar
• PetriMStohlWChathamWAssociation of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosusArthritis Rheum20085882453245918668552
   PubMed Web of Science ®Google Scholar
• HoldenNJWilliamsJMMorganMDANCA-stimulated neutrophils release BLyS and promote B cell survival: a clinically relevant cellular processAnn Rheum Dis201170122229223321859691
   PubMed Web of Science ®Google Scholar
• CambridgeGStohlWLeandroMJMigoneTSHilbertDMEdwardsJCCirculating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapseArthritis Rheum200654372373216508933
   PubMed Web of Science ®Google Scholar
• FurieRStohlWGinzlerEMBiologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosusArthritis Res Ther2008105R10918786258
   PubMed Web of Science ®Google Scholar
• WallaceDJStohlWFurieRAA phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosusArthritis Rheum20096191168117819714604
   PubMed Web of Science ®Google Scholar
• YeeCSFarewellVIsenbergDARevised British Isles Lupus Assessment Group 2004 index: a reliable tool for assessment of systemic lupus erythematosus activityArthritis Rheum200654103300330517009266
   PubMed Web of Science ®Google Scholar
• PetriMPikeMCKelleyLKilgallenBGordonC2011Systemic Lupus Erythematosus Responder Index Assessment of Responders in EMBLEM, a Phase IIb Study in Patients with Moderate to Severe Systemic Lupus Erythematosus [abst]Presented at the American College of Rheumatology Annual MeetingNovember 5–9Chicago, IL Presentation 1378
   Google Scholar
• American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Response CriteriaThe American College of Rheumatology response criteria for systemic lupus erythematosus clinical trials: measures of overall disease activityArthritis Rheum200450113418342615529383
   PubMed Web of Science ®Google Scholar
• ChicheLJourdeNManciniJBelimumab for systemic lupus erythematosusLancet201137797832080 author reply 2080–208121684374
   PubMed Web of Science ®Google Scholar
• JacobiAMHuangWWangTEffect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging studyArthritis Rheum201062120121020039404
   PubMed Web of Science ®Google Scholar
• PetriMFurieRMerrillJT2011Six-year experience with belimumab in patients with SLE [Abstract]Presented at the European League Against Rheumatism MeetingMay 25–28London, UK
   Google Scholar
• SekeresMAThe avastin storyN Engl J Med2011365151454145521995408
   PubMed Web of Science ®Google Scholar
• ArnaudLZahrNCostedoat-ChalumeauNAmouraZThe importance of assessing medication exposure to the definition of refractory disease in systemic lupus erythematosusAutoimmun Rev2011101167467821575744
   PubMed Web of Science ®Google Scholar
• TerrierBAmouraZRavaudPSafety and efficacy of rituximab in systemic lupus erythematosus: results from 136 patients from the French AutoImmunity and Rituximab registryArthritis Rheum20106282458246620506527
   PubMed Web of Science ®Google Scholar
• ChaussabelDQuinnCShenJA modular analysis framework for blood genomics studies: application to systemic lupus erythematosusImmunity200829115016418631455
   PubMed Web of Science ®Google Scholar
• QuartierPAllantazFCimazRA multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)Ann Rheum Dis201170574775421173013
   PubMed Web of Science ®Google Scholar